5 Things You Didn’t Know About Medpace’s Biorepository Services
Medpace Biorepository, a CAP accredited facility, is a key component of Medpace Central Labs and the full-service model.
Chronic Kidney Disease & Its Impact on Clinical Development – Part 2
This post is the second of a three-part blog series. In Part 2, we take a look at the biomarkers for chronic kidney disease.
Wearable Biosensors are Changing the Future of Clinical Trials
Clinical trialists have moved to an older trial model requiring less patient mobility and preferably centered at home, but now with innovative next-gen remote biosensing…
The Power of X: Experts. Experience. Execution.®
Our mission is to accelerate the global development of safe and effective medical therapeutics. It is fueled by the Power of X: eXperts, eXperience and…
[Infographic] The Key Role of Imaging in Clinical Trials
This brand new infographic explores the different types of imaging techniques, their advantages, limitations, and how they can be successfully implemented in clinical trials.
Partnership with Greenleaf Enhances Strategic Regulatory Affairs Capabilities
"This partnership strengthens our global Regulatory Affairs offering and allows us to expand our strategic capabilities to support our Sponsors’ programs.” - Jon Isaacsohn, MD,…
Chronic Kidney Disease & Its Impact on Clinical Development – Part 1
Recently, medical and operational experts from our nephrology team presented a webinar on Chronic Kidney Disease (CKD). Over the next several weeks, we will build…
Medpace Bolsters In-House Central Lab Expertise with the Addition of Three New Scientists
Medpace is pleased to announce the addition of three scientists to our Central Laboratory leadership team.
International Nurse Practitioner Week: November 8-14
This week we honor the critical role of nurse practitioners (NPs), who are championing the health of America’s patients, as part of this year’s annual…
Medpace Clinical Pharmacology Unit working with HiFiBIO Therapeutics on a SARS-CoV-2 ID-neutralizing antibody for the treatment and prevention of COV19
In a recent news release, HiFiBiO Therapeutics announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132 which was…